Mer­ck’s snap­shot of pos­i­tive da­ta for front­line lung can­cer niche trig­gers a new scram­ble for quick Keytru­da OK

Mer­ck has caught the big wave on front­line lung can­cer, and it plans to ride an ear­ly pos­i­tive sig­nal straight through to a quick OK for an­oth­er lu­cra­tive mar­ket niche for Keytru­da.

This morn­ing the phar­ma gi­ant post­ed word that their Keynote-407 tri­al scored a pos­i­tive hit on the over­all re­sponse rate for un­treat­ed metasta­t­ic squa­mous non-small cell lung can­cer in an in­ter­im analy­sis and they’ve al­ready filed for the ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.